Use of Complementary Therapy in Lung Cancer Patients Treated with Chemotherapy and its Effect on Survival: A Cross-sectional Study

Basit Öğe Kaydı
dc.authorscopusid57226624079
dc.authorscopusid57431169800
dc.authorscopusid57226431644
dc.authorscopusid56082620300
dc.authorscopusid57218822513
dc.contributor.authorÇavdar, Eyyüp
dc.contributor.authorKaraboyun, K.
dc.contributor.authorİriağaç, Yakup
dc.contributor.authorAvcı, Okan
dc.contributor.authorSeber, Erdoğan Selçuk
dc.date.accessioned2023-05-06T17:23:35Z
dc.date.available2023-05-06T17:23:35Z
dc.date.issued2023
dc.departmentFakülteler, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, Radyasyon Onkolojisi Ana Bilim Dalı
dc.description.abstractAim: Complementary therapies are being increasingly preferred in patients receiving anticancer therapy to strengthen the effect of chemotherapy and control cancer-related symptoms. In this study, we investigated the prevalence of complementary therapy (CT), the factors associated with its use, physician-patient information sharing about CT use, and the effect of CT on the survival and treatment process in lung cancer patients receiving chemotherapy. Methods: This study was designed as a cross-sectional study including patients who underwent chemotherapy for lung cancer between November 2020 and March 2022 in the department of medical oncology at Tekirdag Namik Kemal University. A structured questionnaire with twenty questions was used. Fluor-18-fluorodeoxyglucose positron emission tomography/CT, and brain magnetic resonance imaging were used to stage the patients. The stages were grouped as early (stages 1B-3A) and advanced (stages 3B-4A). Results: A total of 242 patients included in the study. One hundred and forty-seven (60.7%) patients reported using at least one type of CT since the first diagnosis. “Families/relatives” (n=128; 63.7%) and “other patients” (n=67; 33.3%) were the primary sources from which patients obtained CT information. The most widely used CT methods were recorded as phytotherapy (79.6%) and apitherapy (59.2%). 125 (85%) of the patients said that they used CT to support their existing anticancer treatments. Of the patients using CT, 94 (63.9%) stated that they did not disclose their use of CT to their physicians. The majority of patients stated that their physicians did not inquire about using CT. In the cox regression analysis performed to determine survival benefit, no survival benefit from the use of CT was determined (hazard ratio=0.86, p=0.495). In the subgroup analysis, the use of CT was associated with survival in early-stage patients, but no survival relationship was found in advanced-stage patients (log-rank p=0.027 and p=0.842, respectively). Conclusion: The use of CT in conjunction with medical treatment is common among patients with lung cancer. The influence of the oncologist in guiding the use of CT in cancer patients is weak. Additionally, the use of CT does not provide benefits in terms of survival. © 2023 by The Medical Bulletin of Istanbul Haseki Training and Research Hospital The Medical Bulletin of Haseki published by Galenos Yayinevi.
dc.identifier.doi10.4274/haseki.galenos.2023.8591
dc.identifier.endpage68
dc.identifier.issn1302-0072
dc.identifier.issue1en_US
dc.identifier.scopus2-s2.0-85148625600
dc.identifier.scopusqualityQ4
dc.identifier.startpage59
dc.identifier.trdizinid1173746
dc.identifier.urihttps://doi.org/10.4274/haseki.galenos.2023.8591
dc.identifier.urihttps://hdl.handle.net/20.500.11776/12167
dc.identifier.volume61
dc.identifier.wosWOS:000964102000009
dc.identifier.wosqualityN/A
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakTR-Dizin
dc.institutionauthorÇavdar, Eyyüp
dc.institutionauthorKaraboyun, K.
dc.institutionauthorİriağaç, Yakup
dc.institutionauthorAvcı, Okan
dc.institutionauthorSeber, Erdoğan Selçuk
dc.language.isoen
dc.publisherGalenos Publishing House
dc.relation.ispartofHaseki Tip Bulteni
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccess
dc.subjectcomplementary therapies
dc.subjectLung neoplasms
dc.subjectphytotherapy
dc.subjectsurveys and questionnaires
dc.subjectfluorodeoxyglucose f 18
dc.subjectacupuncture
dc.subjectadult
dc.subjectadvanced cancer
dc.subjectaged
dc.subjectapitherapy
dc.subjectArticle
dc.subjectcancer chemotherapy
dc.subjectcancer radiotherapy
dc.subjectcancer staging
dc.subjectcancer surgery
dc.subjectcancer survival
dc.subjectcomplementary therapy
dc.subjectcomputer assisted tomography
dc.subjectcross-sectional study
dc.subjectcupping therapy
dc.subjectECOG Performance Status
dc.subjecteducational status
dc.subjectfemale
dc.subjectfollow up
dc.subjecthomeopathy
dc.subjecthuman
dc.subjectknowledge
dc.subjectlife expectancy
dc.subjectlung adenocarcinoma
dc.subjectlung cancer
dc.subjectmale
dc.subjectmedical procedures
dc.subjectmetastasis
dc.subjectmushroom
dc.subjectnuclear magnetic resonance imaging
dc.subjectoverall survival
dc.subjectphytotherapy
dc.subjectpositron emission tomography-computed tomography
dc.subjectprevalence
dc.subjectretrospective study
dc.subjectsquamous cell lung carcinoma
dc.subjectstructured questionnaire
dc.subjectvitamin supplementation
dc.titleUse of Complementary Therapy in Lung Cancer Patients Treated with Chemotherapy and its Effect on Survival: A Cross-sectional Study
dc.typeArticle

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim
İsim:
12167.pdf
Boyut:
708.48 KB
Biçim:
Adobe Portable Document Format
Açıklama:
Tam Metin / Full Text
İndir

Koleksiyon

Scopus İndeksli Yayınlar Koleksiyonu
Tıp Fakültesi Koleksiyonu
TR-Dizin İndeksli Yayınlar Koleksiyonu
WoS İndeksli Yayınlar Koleksiyonu